AbbVie (ABBV) Liabilities and Shareholders Equity (2012 - 2026)

AbbVie (ABBV) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $135.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 1.51% year-over-year to $135.1 billion in Q2 2026; TTM through Jun 2026 was $539.4 billion, a 2.26% decrease from a year earlier, with the FY2025 full-year figure at $134.0 billion, down 0.89% from the prior year.
• Liabilities and Shareholders Equity was $135.1 billion for Q2 2026 at AbbVie, down from $136.5 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $148.9 billion in Q1 2024 and troughed at $133.9 billion in Q3 2025.
• A 5-year average of $138.3 billion and a median of $136.3 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity grew 10.65% in 2024 and fell 8.54% in 2025, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $138.8 billion in 2022, then retreated by 2.95% to $134.7 billion in 2023, then advanced by 0.33% to $135.2 billion in 2024, then slipped by 0.89% to $134.0 billion in 2025, then rose by 0.86% to $135.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $135.1 billion (Q2 2026), $136.5 billion (Q1 2026), and $134.0 billion (Q4 2025), per Business Quant data.